Jump to ContentJump to Main Navigation
The NMDA Receptor$
Users without a subscription are not able to see the full content.
The NMDA Receptor

G. L. Collingridge and J. C. Watkins

Print publication date: 1995

Print ISBN-13: 9780192625021

Published to Oxford Scholarship Online: March 2012

DOI: 10.1093/acprof:oso/9780192625021.001.0001

Competitive NMDA antagonists as drugs

Chapter:
(p. 457 ) 19 Competitive NMDA antagonists as drugs
Source:
The NMDA Receptor
Author(s):

B. S. MELDRUM

A. G. CHAPMAN

Publisher:
Oxford University Press
DOI:10.1093/acprof:oso/9780192625021.003.0019

The potential clinical applications of N-methyl-d-aspartate (NMDA) antagonists were initially defined on the basis of animal models. Epilepsy was the first target syndrome identified and remains an important potential therapeutic area. Today stroke and traumatic injury of the spinal cord and brain are the most important clinical targets. The possibility of using NMDA antagonists as long-term therapies in chronic neurodegenerative disorders seems relatively remote, largely because of the problem of side effects. This chapter lists potential therapeutic targets for NMDA antagonists. Before reviewing preclinical and clinical data relating to the therapeutic prospects of NMDA antagonists this chapter briefly reviews currently available compounds.

Keywords:   NMDA antagonists, animal models, epilepsy, spinal cord injury, neurodegenerative disorders, therapeutic targets

Oxford Scholarship Online requires a subscription or purchase to access the full text of books within the service. Public users can however freely search the site and view the abstracts and keywords for each book and chapter.

Please, subscribe or login to access full text content.

If you think you should have access to this title, please contact your librarian.

To troubleshoot, please check our FAQs , and if you can't find the answer there, please contact us .